Veozah (fezolinetant)
This is not medical advice — it is general information based on what you searched for that may help.
General information based on published sources and the symptoms you searched for. This isn't medical or legal advice, a diagnosis or a treatment plan. Please consult a doctor about your own symptoms. If your symptoms are severe or sudden, seek urgent care.
Evidence:Strong evidence
This page may not apply to you if:
- Contraindicated in people with known cirrhosis, severe renal impairment or end-stage renal disease, or taking CYP1A2 inhibitors
Veozah (fezolinetant) is an FDA-approved, non-hormonal prescription medication for moderate-to-severe hot flashes and night sweats due to menopause, supported by Level I evidence in The Menopause Society's 2023 Nonhormone Therapy Position Statement.
How fezolinetant works without hormones
During menopause, declining estrogen causes neurokinin B (NKB) signaling on KNDy neurons in the brain's thermoregulatory center (hypothalamus) to become overactive, triggering hot flashes. Fezolinetant blocks the neurokinin 3 (NK3) receptor directly rather than replacing estrogen. Compare it with the dual NK1/NK3 blocker in Lynkuet (elinzanetant) and other non-hormonal treatments for hot flashes.
FDA boxed warning: liver blood test schedule and contraindications
According to the FDA label, Veozah is contraindicated if you have known cirrhosis, severe kidney impairment or end-stage renal disease, or if you take medications that are CYP1A2 inhibitors.
Questions to take to your clinician
Add these prompts to your printable sheet in the treatment conversation builder or compare non-prescription options in our Does It Work? directory:
- Do any of my current medications inhibit CYP1A2 or interact with fezolinetant?
- How will we schedule my baseline, 1-month, 2-month, 3-month, 6-month, and 9-month liver function blood tests?
- How does Veozah compare with other Level I non-hormonal options (such as SSRIs/SNRIs, gabapentin, or elinzanetant) for my health history?
Where are you right now?
Still tracking
Not sure if your symptoms fit? Start tracking your daily patterns.
Log and spot your patterns with the symptom checklist →Ready to talk to a doctor
Have an upcoming appointment? Bring structured questions and your history.
Prepare your 10-minute doctor appointment questions →Already on treatment
Evaluating your response or wondering what to adjust next?
Explore evidence-graded treatment and lifestyle options →Questions people ask
Is Veozah a hormone?
No. Veozah (fezolinetant) is a non-hormonal neurokinin 3 (NK3) receptor antagonist that targets temperature-regulating neurons in the hypothalamus without estrogen or progestogen activity.
What blood tests are required when taking Veozah?
Under the FDA prescribing label, a clinician must check blood liver tests (hepatic transaminases and total bilirubin) before you start Veozah, every month for the first 3 months, and then at months 6 and 9.
Related pages
References
- Shufelt CL, Brown V, Carpenter JS et al.. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause (The North American Menopause Society, now The Menopause Society), 2023.
- VEOZAH (fezolinetant) tablets, prescribing information. Astellas Pharma US, 2026. Funding: Manufacturer-issued label (FDA-approved text).
Change log
- : Published clinical guide on Veozah (fezolinetant) and FDA liver monitoring schedule